Compositions and methods for producing vascular occlusion

Details Compositions and methods for producing vascular occlusion Compositions and methods for producing vascular occlusion

2005-05-03

2005-05-03

Chan, Christina (Department: 1644)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

C424S134100, C424S135100, C424S136100, C424S138100, C424S155100, C424S195110, C530S380000, C530S387300, C530S387700, C530S388700, C530S388800, C530S391700, C530S399000

Reexamination Certificate

active

06887474

ABSTRACT:
The present invention relates generally to methods and compositions for targeting, delivering, and activating platelet-dependent vascular occlusion agents. In particular, antibodies carrying platelet binding agents are targeted to hyperplastic cells or tissues, such as the vasculature of solid tumor masses; the platelet binding agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the formation of a platelet-mediated thrombus-causing vessel occlusion.

REFERENCES:
patent: 6093399 (2000-07-01), Thorpe et al.
patent: 6218513 (2001-04-01), Anthony-Cahill et al.
patent: PCTUS95/07439 (1996-01-01), None
patent: PCTUS98/01012 (1998-07-01), None
Bensimon et al Science 265:2096-2099 1994.*
Xianming Huang et al. Science 275:547-550, Jan. 1997.*
Thorpe P.: “Antibody directed targeting of tumor vasculature (Meeting abstract)”, Proc Annu Meet Am Assoc Cancer Res, vol. 37, p 668, 1996.
Barinaga M.: “Designing therapies that target tumor blood vessels”, Science, vol. 275, pp 482-484, Jan. 1997.
Ohuchida, Shuichi et al.: “Synthesis of Thromboxane A Analogues: DL-9, 11:11, 12-Dideoxa-9, 11:11, 12-diepithiothromboxane A”,Journal of American Chemical Society,vol. 103, pp. 4597-4599, (1981).
Stewart, Michael W. et al.: “Platelet activation by a novel solid-phase agonist: effects of VWF immobilized on polystyrene beads”,British Journal of Haematology,vol. 97, pp. 321-329 (1997).
Kulkarni, Suhasini et al.: “A revised model of platelet aggregation”,The Journal of Clinical Investigation,vol. 105 (6), pp. 783-791 (2000).
Ruggeri, Zaverio M.: “Old concepts and new developments in the study of platelet aggregation”,The Journal of Clinical Investigation,vol. 105 (6), pp. 699-701 (2000).
Falati, Shahrokh et al.: “Glycoprotein Ib-V-IX, a Receptor for von Willebrand Factor, Couples Physically and Functionally to the Fc Receptor y-Chain, Fyn and Lyn to Activate Human Platelets”,Blood,vol. 94 (5), pp. 1648-1656 (1999).
Kaufman, Randal J. et al.: “Regulation of Factor VIII Expression and Activity by von Willebrand Factor”,Thrombosis and Haemostasis,vol. 82 (2), pp. 201-208 (1999).
Ruggeri, Zaverio M.: “Structure and Function of von Willebrand Factor”,Thrombosis and Haemstasis,vol. 82 (2), pp. 576-584 (1999).
Mann, Kenneth G.: “Biochemistry and Pphysiology of Blood Coagulation”,Thrombosis and Haemostasis,vol. 82 (2), pp. 165-174 (1999).

Affiliated with

Also associated with

Rating

Compositions and methods for producing vascular occlusion does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for producing vascular occlusion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for producing vascular occlusion will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3375982